Monensin causes dose dependent inhibition of *Mycobacterium avium* subspecies *paratuberculosis* in radiometric culture

Robert J Greenstein*1, Liya Su2, Robert H Whitlock3 and Sheldon T Brown2

Address: 1Laboratory of Molecular Surgical Research, VAMC Bronx, NY (112), 130 West Kingsbridge Road, Bronx, NY 10468, USA, 2VAMC Bronx NY, 130 West Kingsbridge Road, Bronx, NY 10468, USA and 3School of Veterinary Medicine, University of Pennsylvania, 382 West Street Road, Kennett Square, PA 19348, USA

Email: Robert J Greenstein* - BGAxis@aol.com; Liya Su - LiyaSu01@aol.com; Robert H Whitlock - rhw@vet.upenn.edu; Sheldon T Brown - Sheldon.Brown@va.gov

* Corresponding author

Abstract

**Background:** *Mycobacterium avium* subspecies *paratuberculosis* (MAP) causes a chronic wasting diarrheal disease in ruminants called Johne’s disease, that is evocative of human inflammatory bowel disease (IBD). Agents used to treat IBD, called “anti-inflammatories”, immuno-modulators” and “immuno-suppressants” inhibit MAP growth in culture. We concluded that, unknowingly, the medical profession has been treating MAP since sulfasalazine’s introduction in 1942. Monensin, called a “Growth Enhancer” in cattle, ameliorates Johne’s disease without a documented mechanism of action. We hypothesized that Monensin would inhibit MAP in culture.

**Methods:** Using the radiometric 14CO2 Bactec® system, that expresses mycobacterial growth in arbitrary growth index (GI) units, we studied the effect of Monensin on the growth kinetic of MAP isolated from humans with IBD (“Dominic”, “Ben” & UCF-4) and cattle with Johne’s disease (303 & ATCC 19698.) Results are expressed as percent inhibition of cumulative GI (%–ΔcGI).

**Results:** The positive control Clofazimine inhibits every strain tested. The negative controls Cycloheximide & Phthalimide, have no inhibition on any MAP strain. Monensin has dose dependent inhibition on every MAP strain tested. The most susceptible human isolate was UCF-4 (73% – ΔcGI at 1 μg/ml) and bovine isolate was 303 (73% – ΔcGI at 4 μg/ml). Monensin additionally inhibits *M. avium* ATCC 25291 (87% – ΔcGI at 64 μg/ml) & BCG (92% – ΔcGI at 16 μg/ml).

**Discussion:** We show that in radiometric culture the "Growth Enhancer" Monensin causes dose dependent inhibition of mycobacteria including MAP. We posit that the "Growth Enhancer" effect of Monensin may, at least in part, be due to inhibition of MAP in clinical or sub-clinical Johne’s disease.

Background

In ruminants worldwide *Mycobacterium avium* subspecies *paratuberculosis* (MAP) causes Johne’s disease [1], which is evocative of inflammatory bowel disease (IBD) in humans [2]. As of 2007, 68% of all US cow herds had at least one environmental sample that cultured positive for MAP, rising to 95% in herds of > 500 cows [3]. The financial cost of Johne’s disease to the agricultural industry, in the USA alone, is estimated to be > $200 million a year.

Humans are continually exposed to viable MAP, as MAP has been cultured from commercially available pasteur-
ized milk in the US [4], and Europe [5] and is found in potable chlorinated municipal water in the US [6] and Europe [7]. Although controversial, there is mounting concern [8] and increasingly compelling data that MAP may be zoonotic. [9,10] Recently, the agents 5-ASA [11], azathioprine [12], 6-MP [12,13], methotrexate [13], cyclosporine A, [14] Rapamycin [14] and Tacrolimus [14], that are referred to as “anti-inflammatory” “immunomodulator” and “immunosuppressants” by physicians, have been shown to cause dose dependent inhibition of MAP in culture. Corroborative evidence that MAP may be zoonotic are that, in humans, the most potent “antiMAP” agents in culture [12-14], actually clear MAP DNA from the blood of individuals with Inflammatory Bowel Disease [15]. We suggested [11,13,14] that, unknowingly, the medical profession had been treating MAP since 1942, when Nana Svartz introduced sulfasalazine into clinical practice [16].

Introduced in 1967, Monensin [17] is acknowledged as an anti-coccidical agent for poultry [18-20]. Approved as a “Growth Enhancer” antibiotic in the USA, the UK and Europe [21], Monensin accounts for 13% of the total sub-therapeutic livestock antibiotic usage in the USA [22]. Eukaryotic metabolic effects of Monensin, include inhibition of endosome acidification [23] Na+ ionophore enhancement [24] including action on Leishmania donovani. [25] and possibly prokaryotes [23,26]. In ruminants the administration of Monensin results in improved energy balance [27], decreases methanogenesis [28], increases plasma urea-N [29], and increased milk production in lactating cows [30]. It is of considerable interest that the use of Monensin results in amelioration of pathology [21,31-33] and results in clinical improvement in animals with Johne’s disease [34,35].

We hypothesized that Monensin, in addition to its protein anti-coccidial [18-20] and eukaryotic effects [23-25,36] may additionally inhibit prokaryotes [26], in particular MAP. If correct, ruminant “Growth Enhancement” may in part be consequent to “antiMAP” antibiotic activity in cattle with clinical or sub-clinical Johne’s disease. To test this hypothesis, we studied the effect of Monensin on mycobacteria including M. avium and its subspecies paratuberculosis, using our previously validated culture inhibition methods [11,13,14].

**Methods**

This study was conducted as an approved protocol of the Research and Development Committee of the VAMC Bronx approved protocol (0720-06-038.) Inhibition studies were performed on eight mycobacterial strains in culture, as reported. [11,13,14] Five strains were MAP, of which three were isolated from humans with IBD, "Dominic" (ATCC 43545), Ben, (ATCC 43544) [37] & UCF-4 (gift of S. Naser Orlando FL). Two were MAP subspecies avium strains (subsequently referred to as M. avium) were ATCC 28291 (ATCC) and M. avium 101 [39]. To study the effect on the M. tuberculosis complex we used a Biosafety level II surrogate, BCG M. bovis Karlson & Lessel (ATCC 19015.) Agents (all from Sigma, St Louis MO) were dissolved in DMSO [11,13] with a final concentration in every Bactec vial, irrespective of the amount of agent in a vial, of 3.2% DMSO.

Quantifying mycobacterial growth and the effect of agents tested, using the radiometric 14CO2 Bactec 460 system, has previously been reported in detail [11,13,14]. In brief, the daily Growth Index (GI) for each vial is obtained until any vial reaches the instrument maximum of GI of “999.” Daily GI’s are summed until the day prior to any vial reaching “999." The effect (or lack thereof) of each agent is presented as the percent decrease in cumulative Growth Index (cGI) units (% – ΔcGI) ± SD [11] (when necessary, see individual figures).

**Results**

For ease of comprehension, data are presented in two ways: For individual mycobacterial strains, data are presented as Figures using the cumulative Growth Index (cGI). For individual chemicals the same data, recalculated as %–ΔGI [11,13], are presented as Tables. Figure 1 = MAP isolated from humans with Crohn’s Disease. Figure 2 = Bovine Isolates of MAP from animals with Johne’s disease. Figure 3 is M. avium subspecies avium. Figure 4 presents data for BCG. Table 1 is the positive antibiotic control Clofazimine (used in leprosy [40] and clinical trials of Crohn’s disease [41,42].) The negative controls are the gluterimide antibiotics cycloheximide (Table 2) and phthalimide (Table 3.) The study results on Monensin are presented in Table 4.

In total we performed 29 culture inhibition experiments that included Monensin, of which 21 involved MAP that had been isolated from either ruminants or humans. In every case where Monensin was studied for its effect on MAP, dose dependent inhibition was observed. For brevity and clarity, representative studies are presented. The positive control, clofazimine causes dose dependent inhibition; > 98% – ΔcGI in every strain tested by 1 μg/ml (Figures 1, 2, 3, 4 & Table 1.) A negative control Cycloheximide has no inhibition on any MAP strain at the doses used in these studies (Figures 1 & 2 & Table 2.) In contrast, when tested against M. avium ATCC 25291, Cycloheximide has no effect between 1 & 16 μg/ml, but does have 57% – ΔcGI at 64 μg/ml (Figures 3 & Table 2.) Similarly, against BCG, Cycloheximide has no dose dependent inhibition between 1 & 16 μg/ml, but does have 78% – ΔcGI at 64 μg/ml (Figures 4 & Table 2.) Phthalimide, the other negative control, has no dose dependent inhibition.
against any of the eight mycobacterial strains evaluated (Figures 1, 2, 3, 4 & Table 3.)

Monensin exhibits dose dependent inhibition on MAP in culture, whether isolated from humans with Crohn’s disease (Figure 1 & Table 4) or cows with Johne’s disease (Figure 2 & Table 4.) Of the human MAP isolates, UCF-4 was most susceptible, 73% – ΔcGI at 1 μg/ml (Figure 1 & Table 4) and Ben least inhibited (51% – ΔcGI at 4 μg/ml: Figure 1 & Table 4.) Of the two bovine MAP isolates, ATCC 19698 (45% – ΔcGI at 4 μg/ml) was less inhibited than 303 (73% – ΔcGI at 4 μg/ml: Figure 2 & Table 4.) Monensin additionally causes dose dependent inhibition on two of the three control mycobacterial strains; ATCC 25291 & BCG (Figures 3 &4 & Table 4.) The single exception to inhibition by Monensin is with the control M. avium subspecies avium strain 101 (Figure 3 & Table 3.)

Our present data corroborate the culture finding of Brumbaugh et. al. [33]. With a single strain of MAP, in one culture experiment, there was no visually detectable growth at 30 days following inoculation. This was interpreted as showing a Monensin Minimum Inhibitory Concentration of 0.39 μg/ml against MAP. In our study, a distillation of 29 different experiments involving Monensin, of which 21 were conducted against five strains of MAP, we show

Discussion
The "anti-inflammatories" "immune-modulators' and "immune-suppressants" 5-ASA [11], azathioprine [12], 6-MP [12,13], methotrexate [13], cyclosporine A, [14] Rapamycin [14] and Tacrolimus [14], all cause dose dependent inhibition of MAP in culture. We suggest that, unlike the majority of antibiotics, which effect only prokaryotes, these agents inhibit both pro and eukaryotes. It is therefore possible that these terms "anti-inflammatories" "immune-modulators' and "immune-suppressants" are actually misnomers. We suggest that these appellations merely report normal secondary eukaryotic physiological effects, consequent to, unknowingly, treating an underlying prokaryotic infection. Specifically we suggest that since 1942, the medical profession has unknowingly been treating MAP infections when using these medications.

Figure 1
Presents data for the three human isolates of MAP from patients with Crohn's disease. All three have dose dependent inhibition, albeit to varying degrees for Dominic, UCF-4 and Ben. Error bars are ± SD.
that, in radiometric culture, Monensin causes dose dependent inhibition of MAP, one of two strains of *M. avium* subspecies *avium* and a single strain of *M. Bovis*.

The fact that MAP is the etiological agent in Johne’s disease is uncontested. There have been a plethora of observation studies on the “metabolic” effects [26,28-30] when Monensin is used in cattle. Monensin is called a “Growth Enhancer” by both veterinarians as well as governmental agencies [21]. These culture inhibition studies offer a rational explanation for the healing of Johne’s lesions [31,32] in ruminants with Johne’s disease treated with Monensin. As mean prevalence of MAP in US dairy herds steadily increases, currently 68%, [3] it is probable that some of these observations were, unknowingly, made on animals with sub-clinical Johne’s disease. We posit that at least some of the “Growth Enhancement” as well as metabolic effects that attends the use of Monensin in ruminants may be the physiological consequence of treating overt or covert MAP infections.

A plausible question is whether the appropriate use of antiMAP agents "cures" Johne’s disease? The dose depend-

---

**Figure 2**

Presents the dose dependent inhibition data for Monensin on isolates of MAP from cows with Johne’s disease, ATCC 19698 and 303. Error bars are ± SD.

**Figure 3**

Shown are the data from two Control strains, *M. avium* ATCC 25291 (Bovine source) and 101 [39]. Note that Monensin, uniquely in this study has no dose dependent inhibition on *M. avium* subspecies *avium* 101.

**Figure 4**

With BCG, our Biosafety level II surrogate for the *M. tuberculosis* complex, Monensin exhibits doses dependent inhibition.
ent inhibition of Monensin that we demonstrate, are compatible with Monensin being a bacteriostatic, rather than bactericidal antiMAP agent. Our data are therefore compatible with the observations that the use of Monensin ameliorates [32], but does not eradicate or clear MAP from animals with Johne's disease [31,33]. This would render Monensin analogous to another "antiMAP" agent, 5-ASA where the effect is demonstrably bacteriostatic [11]. In our culture system Monensin is not nearly as inhibitory as methotrexate and 6-MP [12,13], which clear MAP DNA from the blood of individuals with Inflammatory Bowel Disease [15]. We conclude that Monensin cannot be considered as a "cure" for a ruminant MAP infection.

This study does not address the inhibitory mechanism of Monensin on MAP. One possibility is that it is consequent to cell wall destruction, as occurs with coccidia [18]. Alternatively Monensin's antiMAP activity may be due to perturbation of obligate intracellular metabolic pathways such a DNA synthesis, as occurs with Methotrexate and 6-MP. Distinguishing between the two modes of action is important. In man, MAP exists in the cell wall deficient form (see [10] for review). In contrast, in ruminants it is the cell wall containing form of MAP that is readily identified [1]. We conclude that our present observations do not justify initiating human clinical trials of Monensin in putative zoonotic MAP infections such as Crohn's disease or ulcerative colitis. Such appropriately planned and

| Clofazimine | MAP | M. avium | M. bovis |
|------------|-----|----------|----------|
| μg/ml      | Human | UCF-4 | Ben | 19698 | 303 | 25291 | 101 | 19015 |
| 1          | -99%  | -99%  | -99% | -99%  | -99% | -98%  | -98% | -99%  |
| 4          | -99%  | -99%  | -99% | -99%  | -99% | -98%  | -98% | -98%  |
| 16         | -99%  | -99%  | -99% | -99%  | -99% | -98%  | -98% | -98%  |
| 64         | -99%  | -99%  | -99% | -99%  | -99% | -99%  | -99% | -99%  |

Data are presented for a single agent, Clofazimine, the positive antibiotic control. Data are given for a representative experiment of each mycobacterial strain studied. Note maximal inhibition at 1 μg/ml for every strain. %–ΔcGI = Percent decrease in cumulative Growth Index compared to solvent control (see Methods.)

| Cycloheximide | MAP | M. avium | M. bovis |
|---------------|-----|----------|----------|
| μg/ml         | Human | UCF-4 | Ben | 19698 | 303 | 25291 | 101 | 19015 |
| 1             | 15%  | 1%    | 7%  | -2%  | 3%  | 0%   | 6%  | -12%  |
| 4             | -4%  | -7%   | 1%  | -7%  | 4%  | -8%  | 7%  | -13%  |
| 16            | -8%  | -4%   | -3% | -12% | -5% | -7%  | 1%  | -8%   |
| 64            | -1%  | -12%  | -5% | -9%  | -4% | -57% | 5%  | -78%  |

Data are presented for a single agent, the glutarimide antibiotic Cycloheximide, a negative antibiotic control. Data are given for a representative experiment of each mycobacterial strain studied. Note that there is no strain exhibiting dose dependent inhibition within the range tested. %–ΔcGI = Percent decrease in cumulative Growth Index compared to solvent control (see Methods.)
authorized human trials should only be performed if the antiMAP action of Monensin is unequivocally shown to affect intracellular metabolic pathways of MAP and not its cell wall.

**Abbreviations**

MAP: Mycobacterium avium subspecies paratuberculosis; IBD: inflammatory bowel disease; GI: Growth Index; cGI: cumulative Growth Index; % – ΔcGI: percent decrease in cGI units compared to control growth.

**Competing interests**

RJG submitted provisional patents based on the hypotheses tested in prior studies. There is no conflict of interest with these Monensin data. STB was a member of the panel of the National Academy of Sciences of the USA that issued the report entitled “The Diagnosis and Control of Johne’s disease (ISBN 0-309-08611-6). LS and RHW have no competing interests.

**Authors’ contributions**

RHW and RJG conceived the experiments. RJG and STB designed the experiments. LS and RJG performed the

### Table 3: Negative Control

| Phthalimide | MAP | M. avium | M. bovis |
|-------------|-----|----------|----------|
| µg/ml       | Human | Bovine | Bovine | BCG |
|             | Dominic | UCF-4 | Ben | 19698 | 303 | 25291 | 101 | 19015 |
| 1           | -1% | 4% | 16% | -2% | -2% | 2% | -3% | -2% |
| 4           | 0% | -2% | -4% | -10% | 3% | 4% | 4% | 11% |
| 16          | 1% | 1% | 8% | 1% | -13% | 1% | 2% | -23% |
| 64          | 4% | 3% | 8% | 0% | 6% | 12% | -2% | 10% |

Data are presented for a single agent, Phthalimide another negative antibiotic control. Data are given for a representative experiment of each mycobacterial strain studied. Note that there is no strain exhibiting dose dependent inhibition within the range tested. % – ΔcGI = Percent decrease in cumulative Growth Index compared to solvent control (see Methods.)

### Table 4: The study results on Monensin

| Monensin | MAP | M. avium | M. bovis |
|----------|-----|----------|----------|
| µg/ml    | Human | Bovine | Bovine | BCG |
|          | Dominic | UCF-4 | Ben | 19698 | 303 | 25291 | 101 | 19015 |
| 1        | -52% | -73% | -21% | -14% | -21% | -25% | 7% | -44% |
| 4        | -77% | -93% | -51% | -45% | -73% | -54% | 3% | -69% |
| 16       | -93% | -96% | -93% | -62% | -94% | -69% | 4% | -92% |
| 64       | -94% | -97% | -97% | -65% | -97% | -87% | 8% | -98% |

Data are presented for the agent evaluated in this study, the “Growth Enhancer” Monensin. Data are given for a representative experiment of each mycobacterial strain studied. Note the dose dependent inhibition in every mycobacterial strain except M. avium subspecies avium 101. The dose dependent inhibition was observed in each of the 21 experiments where MAP was the strain studied (replicative data not presented.) % – ΔcGI = Percent decrease in cumulative Growth Index compared to solvent control (see Methods.)
experiments. RIG, LS, RHW and STB analysed the data. STB and RIG contributed reagents/materials/analysis equipment. RIG wrote the manuscript. All authors read and approved the final manuscript.

Acknowledgements
Thanks to the VAMC Bronx for providing facilities, Becton-Dickinson for supplying Bactec vials, Drs. R. Yalow, J. Uehlinger, GPS Linn, R Juste and S. Singh for their comments.

References
1. Johne HA, Frothingham L: Ein eigentümlicher Fall von tuberkulo-lose beim Rind (A particular case of tuberculosis in a cow). Dtsch Zeitschr Tiermed, Vergl Pathol 1895, 21:438-454.
2. Dalziel TK: Chronic intestinal enteritis. BMJ 1913, ii:1068-1070.
3. Johne’s Disease on US Dairies 2001–2007.
4. Ellingson JL, Anderson JL, Koziczkowski JJ, Radcliff RP, Sloan SJ, Allen SE, Sullivan NM: Detection of viable Mycobacterium avium subsp. paratuberculosis in retail pasteurized whole milk by culture methods and PCR. J Food Prot 2005, 68(5):966-972.
5. Ikonomoupolos J, Pavlik I, Barton M, Svastova P, Ayele WW, Roubl P, Lukas J, Cook N, Gazouli M: Detection of Mycobacterium avium subsp. paratuberculosis in Retail Cheeses from Greece and the Czech Republic. Appl Environ Microbial 2005, 71(12):8934-8936.
6. Mishina D, Katsel P, Brown ST, Gilberts EC, Greenstein RJ: On the etiology of Crohn disease. Proc Natl Acad Sci USA 1996, 93(18):9816-9820.
7. Hermann-Taylor J, El-Zaatari FAK: The Mycobacterium avium subsp. paratuberculosis problem and its relation to the causation of Crohn disease. In Pathogenic Mycobacteria in Water: A Guide to Public Health Consequences, Monitoring and Management 1st edition. Edited by: Pedley S, Bartram J, Rees G, Dufour A, Cotruvo J. London UK: IWA Publishing; 2004:74-94.
8. Nacy C, Buckley M: Mycobacterium Avium Paratuberculosis: Infrequent Human Pathogen or Public Health Threat? Myco- bacterium Avium Paratuberculosis: Infrequent Human Pathogen or Public Health Threat?: 2008; Salem Massachusetts USA 2008:1-37 [https://acad emy.asm.org/option=com_content&view=article&id=56&Itemid=3].
9. Greenstein RJ, Collins MT: Emerging pathogens: is Myco bacte rium avium subsp. paratuberculosis zoonotic? Lancet 2004, 364(9432):396-397.
10. Greenstein RJ: Is Crohn’s disease caused by a mycobacterium? Comparisons with leprosy, tuberculosis, and Johne’s disease. Lancet Infect Dis 2003, 3(8):507-514.
11. Greenstein RJ, Su L, Shahidi A, Brown ST: On the Action of S-Amino-Saliclylic Acid and Sulfapyridine on M. avium including Subspecies paratuberculosis. PLoS ONE 2007, 2:e516.
12. Shin SJ, Collins MT: Thioiparine drugs (azathioprine and 6-mercaptopurine) inhibit Mycobacterium paratuberculosis growth in vitro. Antimicrob Agents Chemother 2008, 52(2):418-426.
13. Greenstein RJ, Su L, Haroutunian V, Shahidi A, Brown ST: On the Action of Methotrexate and 6-Mercaptopurine on M. avium Subspecies paratuberculosis. PLoS ONE 2007, 2:e161.
14. Greenstein RJ, Su L, Juste RA, Brown ST: On the Action of Cyclosporine A, Rapamycin and Tacrolimus on M. avium including Subspecies paratuberculosis. PLoS ONE 2008, 3(6):e2496.
15. Juste RA, Elguezabal N, Garrido JM, Pavon A, Geijo MV, Sevilla I, Cabrera JL, Tejada A, Garcia-Campos F, Cassado R, et al.: On the preva lence of M. avium sub species paratuberculosis DNA in the blood of healthy individuals and patients with inflammatory bowel disease. PLoS ONE 2008, 3(7):e2527.
16. Svartz N: Salazopyrin, a new sulfanilamide preparation. A. Therapeutic Results in Rheumatic Polyarthritis. B. Therapuetic Results in Ulcerative Colitis. C. Toxic Manifestations in Treatment with Sulfanilamide Preparations. Acta Medica Scandinavica 1942, 110:277-298.
17. Haney ME Jr, Hoehn MM: Monensin, a new biologically active compound. I. Discovery and isolation. Antimicrob Agents Chem other (Bethesda) 1967, 1:582-592.
18. Shimard RF, Callender ME: Monensin, a new biologically active compound. VI. Anticoccidial activity. Antimicrob Agents Chem other (Bethesda) 1967, 7:369-377.
19. McDougall LR: Anticoccidial action of monensin in turkey poults. Poult Sci 1976, 55(6):2442-2447.
20. Mulliro MG, Jensen LS, Ruff MD, Rahn AP: Effect of dietary methionine status on response of chicks to coccidial infec tion. Poult Sci 1976, 55(2):642-649.
21. Antibiotic use in US livestock production :17-29 [http:// www.aphis.usda.gov/vs/ceel/cafemerginorg/healthissues/files/ antimess_antibiotic.pdf]. USDA-APHIS.
22. Dolliver H, Kumar K, Gupta S, Singh A: Application of enzyme-linked immunosorbent assay analysis for determination of monensin in environmental samples. J Environ Qual 2008, 37(6):2120-2126.
23. Oelschlaeger TA, Tall BD: Invasion of cultured human epithelial cells by Klebsiella pneumoniea isolated from the urinary tract. Infect Immun 1997, 65(7):2950-2958.
24. Halou M, Taurin S, Akimova OA, Guo DF, Tremblay J, Dulin NO, Hunter P, Orlow SN: [Na+]T-induced c-Fos expression is not mediated by activation of the 5’-promoter containing transcriptional elements. Fcbs J 2007, 274(14):3557-3567.
25. Bera T, Lakshman K, Ghanteswari D, Pal S, Sudhahar D, Islam MN, Bhuyan NR, Das P: Characterization of the redox components of transplasma membrane electron transport system from Leishmania donovani promastigotes. Biochim Biophys Acta 2005, 1725(3):314-326.
26. Bergen WG, Bates DB: Ionophores: their effect on production efficiency and mode of action. J Anim Sci 1984, 58(6):1451-1483.
27. Heuer C: The use of test day information to predict energy intake of dairy cows in early lactation. J Dairy Sci 2004, 87(3):593-601.
28. Gutierrez-Banuelos H, Anderson RC, Carstens GE, Tedeschi LO, Pintchak WE, Cabrera-Diaz E, Krueger NA, Callaway TR, Nisbet DJ: Effects of nitroethane and monensin on ruminal fluid fer mentation characteristics and nitrocompound-metabolizing bacterial populations. J Agric Food Chem 2008, 56(12):4650-4658.
29. Martinez P, Berch 

...
37. Chiodini RJ, Van Kruiningin HJ, Thayer WJ Jr, Coutu J: Spheroplast phase of mycobacteria isolated from patients with Crohn’s disease. J Clin Microbiol 1986, 24:357-363.
38. Sung N, Collins MT: Variation in resistance of Mycobacterium paratuberculosis to acid environments as a function of culture medium. Appl Environ Microbiol 2003, 69(11):6833-6840.
39. Bertram MA, Inderlied CB, Yadegar S, Kolanoski P, Yamada JK, Young LS: Confirmation of the beige mouse model for study of disseminated infection with Mycobacterium avium complex. J Infect Dis 1986, 154(1):194-195.
40. Britton WJ, Lockwood DN: Leprosy. Lancet 2004, 363(9416):1209-1219.
41. Borody TJ, Leis S, Warren EF, Surace R: Treatment of severe Crohn’s disease using antimycobacterial triple therapy – approaching a cure? Dig Liver Dis 2002, 34(1):29-38.
42. Selby W, Pavli P, Croft B, Florin T, Radford-Smith G, Gibson P, Mitchell B, Connell W, Read R, Merrett M, et al.: Two-year combination antibiotic therapy with clarithromycin, rifabutin, and clofazimine for Crohn’s disease. Gastroenterology 2007, 132(7):2313-2319.